High Throughput ADME Screening: Practical Considerations, Impact on the Portfolio and Enabler of In Silico ADME Models

被引:61
作者
Hop, Cornelis E. C. A. [1 ]
Cole, Mark J. [1 ]
Davidson, Ralph E. [1 ]
Duignan, David B. [1 ]
Federico, James [1 ]
Janiszewski, John S. [1 ]
Jenkins, Kelly [1 ]
Krueger, Suzanne [1 ]
Lebowitz, Rebecca [1 ]
Liston, Theodore E. [1 ]
Mitchell, Walter [1 ]
Snyder, Mark [1 ]
Steyn, Stefan J. [1 ]
Soglia, John R. [1 ]
Taylor, Christine [1 ]
Troutman, Matt D. [1 ]
Umland, John [1 ]
West, Michael [1 ]
Whalen, Kevin M. [1 ]
Zelesky, Veronica [1 ]
Zhao, Sabrina X. [1 ]
机构
[1] Pfizer Global Res & Dev, Groton, CT 06340 USA
关键词
Absorption; ADME; data management; in silico; in vitro; mass spectrometry; metabolism; pharmacokinetics;
D O I
10.2174/138920008786485092
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Evaluation and optimization of drug metabolism and pharmacokinetic data plays an important role in drug discovery and development and several reliable in vitro ADME models are available. Recently higher throughput in vitro ADME screening facilities have been established in order to be able to evaluate an appreciable fraction of synthesized compounds. The ADME screening process can be dissected in five distinct steps: (1) plate management of compounds in need of in vitro ADME data, (2) optimization of the MS/MS method for the compounds, (3) in vitro ADME experiments and sample clean up, (4) collection and reduction of the raw LC-MS/MS data and (5) archival of the processed ADME data. All steps will be described in detail and the value of the data on drug discovery projects will be discussed as well. Finally, in vitro ADME screening can generate large quantities of data obtained under identical conditions to allow building of reliable in silico models.
引用
收藏
页码:847 / 853
页数:7
相关论文
共 36 条
[1]  
Baillie TA, 2000, MASS SPECTROMETRY IN BIOLOGY & MEDICINE, P481
[2]   Species and gender differences in the formation of an active metabolite of a substituted 2,4-thiazolidinedione insulin sensitizer [J].
Beconi, M ;
Mao, A ;
Creighton, M ;
Hop, CECA ;
Chiu, SHL ;
Eydelloth, R ;
Franklin, R ;
Tang, F ;
Yu, N ;
Vincent, S .
XENOBIOTICA, 2003, 33 (07) :767-787
[3]   In vitro drug interactions of cytochrome P450: An evaluation of fluorogenic to conventional substrates [J].
Cohen, LH ;
Remley, MJ ;
Raunig, D ;
Vaz, ADN .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (08) :1005-1015
[4]   Computational approaches for predicting CYP-related metabolism properties in the screening of new drugs [J].
Crivori, P. ;
Poggesi, I. .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2006, 41 (07) :795-808
[5]   MetaSite: Understanding metabolism in human cytochromes from the perspective of the chemist [J].
Cruciani, G ;
Carosati, E ;
De Boeck, B ;
Ethirajulu, K ;
Mackie, C ;
Howe, T ;
Vianello, R .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (22) :6970-6979
[6]   The price of innovation: new estimates of drug development costs [J].
DiMasi, JA ;
Hansen, RW ;
Grabowski, HG .
JOURNAL OF HEALTH ECONOMICS, 2003, 22 (02) :151-185
[7]   Advances in in vitro drug metabolism screening [J].
Eddershaw, PJ ;
Dickins, M .
PHARMACEUTICAL SCIENCE & TECHNOLOGY TODAY, 1999, 2 (01) :13-19
[8]   Characterization and performance of MALDI on a triple quadrupole mass spectrometer for analysis and quantification of small molecules [J].
Gobey, J ;
Cole, M ;
Janiszewski, J ;
Covey, T ;
Chau, T ;
Kovarik, P ;
Corr, J .
ANALYTICAL CHEMISTRY, 2005, 77 (17) :5643-5654
[9]   A preliminary study on the feasibility of an automated blood-sampling system in conjunction with liquid chromatography/mass spectrometry [J].
He, H ;
Kramp, R ;
Ramos, L ;
Bakhtiar, R .
RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2001, 15 (18) :1768-1772
[10]  
Hop CECA, 2005, PROG PH BIO ANAL, V6, P123